期刊
IMMUNOLOGY
卷 154, 期 4, 页码 582-592出版社
WILEY
DOI: 10.1111/imm.12941
关键词
cancer; CD4 cell; regulatory T cell; T cell; tumour immunology
类别
资金
- Aduro Biotech Europe
Cancer immunotherapy focuses mainly on anti-tumour activity of CD8(+) cytotoxic T lymphocytes (CTLs). CTLs can directly kill all tumour cell types, provided they carry recognizable antigens. However, CD4(+) T cells also play important roles in anti-tumour immunity. CD4(+) T cells can either suppress or promote the anti-tumour CTL response, either in secondary lymphoid organs or in the tumour. In this review, we highlight opposing mechanisms of conventional and regulatory T cells at both sites. We outline how current cancer immunotherapy strategies affect both subsets and how selective modulation of each subset is important to maximize the clinical response of cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据